WellGen Obtains License to Obesity Genes

WellGen, Inc., New Brunswick, NJ, has signed a research contract and licensing agreement with HMGene, Inc. Under terms of the research agreement, HMGene will screen WellGen’s proprietary bioactive compounds against HMGene’s proprietary panel of genes in adipocyte development, which is the body’s natural mechanism for making fat cells. The screening process will identify new, natural bioactive compounds that will be targeted toward weight loss and the control of obesity. Any resulting products will be commercialized by WellGen.